Previous Article | Next Article ![]()
Clinical and Diagnostic Laboratory Immunology, Nov 1995, 672-677, Vol 2, No. 6
H Nakamura, A Ishizaka, T Urano, K Sayama, F Sakamaki, T Terashima, Y Waki, K Soejima, S Tasaka and N Hasegawa
SDZ MRL 953 (SDZ), a novel immunostimulatory lipid A analog, has been
reported to have immunopharmacological activities similar to those of
lipopolysaccharide (LPS) but to have little of the toxicity of LPS. We
investigated the effects of pretreatment with SDZ on Escherichia coli
endotoxin-induced acute lung injury in guinea pigs. Four experimental
groups consisted of saline control (n = 16), SDZ (-12 h) plus LPS (2 mg/kg
of SDZ per kg of body weight injected intravenously 12 h before intravenous
injection of 2 mg of LPS per kg; n = 15), SDZ (-10 min) plus LPS (SDZ
injected 10 min before LPS injection; n = 10), and LPS alone (n = 16). The
animals were sacrificed, and lung tissue was sampled 4 h after LPS or
saline infusion. Lung injury was assessed by measuring the wet
weight-to-dry weight ratio and the level of 125I- labeled albumin
accumulation in bronchoalveolar lavage fluid relative to that in plasma. In
the SDZ (-12 h) plus LPS group, these two parameters of acute lung injury
were decreased compared with those in the LPS alone group. However, they
were not decreased in the SDZ (-10 min) plus LPS group. We conclude that
SDZ attenuates endotoxin-induced acute lung injury when it is administered
12 h before LPS injection. The attenuating effects of SDZ are speculated to
be due to down regulation of the response to endotoxin rather than to
receptor blocking.
Copyright © 1995 by the American Society for Microbiology. All rights reserved.
Effects of pretreatment with SDZ MRL 953, a novel immunostimulatory lipid A analog, on endotoxin-induced acute lung injury in guinea pigs
Department of Medicine, School of Medicine, Keio University, Tokyo, Japan.
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. | Infect. Immun. |
|---|---|---|
| J. Clin. Microbiol. | J. Virol. | ALL ASM JOURNALS |